About Baptist Health South Florida
Baptist Health South Florida is the largest healthcare organization in the region, with 12 hospitals, more than 27,000 employees, 4,000 physicians and 200 outpatient centers, urgent care facilities and physician practices spanning across Miami-Dade, Monroe, Broward and Palm Beach counties. Baptist Health has internationally renowned institutes specializing in cancer care, brain and spine care, heart and vascular care and orthopedic care. In addition, it includes Baptist Health Medical Group; Baptist Health Quality Network; and The Baptist Health PineApp, a virtual health platform. A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Baptist Health has been recognized by Fortune as one of the 100 Best Companies to Work For in America and is the most awarded healthcare system in South Florida by U.S. News and World Report. For more information, visit BaptistHealth.net/Newsroom and connect with us on Facebook, X (formerly Twitter), Instagram, TikTok and LinkedIn.
Dr. Sauter on the Potential Role of BTK Inhibitors in Frontline CNS Lymphoma
March 14th 2023Craig Sauter, MD, discusses where BTK inhibitors could fit into the frontline treatment landscape for patients with central nervous system lymphoma and research aiming to address other unmet needs for this patient population.
Baptist Health Miami Cancer Institute Celebrates 1000th Patient Treated Using Gamma Knife
February 24th 2023Baptist Health Miami Cancer Institute treated its 1000th patient using Gamma Knife radiosurgery, an incisionless radiation therapy that precisely targets a tumor, importantly minimizing damage to otherwise healthy brain tissue.
Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL
February 10th 2023Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).
Dr. Perez Perez on Results From a Retrospective Study of Polatuzumab Regimens in R/R LBCL
February 10th 2023Ariel Perez Perez, MD, discusses key results and clinical implications from a retrospective study of polatuzumab-vedotin plus rituximab with or without bendamustine in relapsed/refractory large B-cell lymphomas.